Efficacy and safety of pharmacological treatments for Lyme neuroborreliosis in children: a systematic review - Archive ouverte HAL Access content directly
Journal Articles BMC Neurology Year : 2016

Efficacy and safety of pharmacological treatments for Lyme neuroborreliosis in children: a systematic review

(1, 2) , (2) , (1) , (3) , (4) , (2) , (1, 5)
1
2
3
4
5

Abstract

BACKGROUND: Many aspects of pharmacological treatment of Lyme neuroborreliosis in children, such as choice of drug, dosage, and duration are subject to intense debates, leading to uncertainties in patients' parents and healthcare providers alike. To assess the available evidence for pharmacological treatment for children with Lyme neuroborreliosis we conducted a systematic review. METHODS: The comprehensive systematic literature search included randomized-controlled trials (RCTs) and non-randomized studies (NRS) on treatment of Lyme neuroborreliosis in children (age <18 years). Our primary outcome was neurological symptoms after treatment. Risk of bias was assessed with the Cochrane risk of bias tools for RCTs and NRS. Quality of evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. RESULTS: Two RCTs and four NRS were eligible for inclusion. Risk of bias in RCTs and NRS was generally high. Reporting of studies was generally poor. Regarding the primary outcome neurological symptoms at 1-3 months, no statistically significant difference could be found in cohort studies between doxycycline and beta-lactam antibiotics. In two RCTs comparing penicillin G and ceftriaxone, no patient experienced residual neurological symptoms at the last reported time points. Quality of evidence according to GRADE was judged very low. CONCLUSIONS: Data is scarce and with limited quality. Several issues could not be addressed due to scarcity of information. No eligible study compared different treatment durations. According to the available evidence, there seems to be no difference between different antibiotic agents for the treatment of Lyme neuroborreliosis in children regarding neurological symptoms. We found no evidence that supports extended antibiotic regimes. REVIEW REGISTRATION: Systematic review registration: CRD42014008839.
Fichier principal
Vignette du fichier
12883_2016_Article_708.pdf (1.14 Mo) Télécharger le fichier
Origin : Publisher files allowed on an open archive
Loading...

Dates and versions

inserm-02052414 , version 1 (28-02-2019)

Identifiers

Cite

Rick Dersch, Tilman Hottenrott, Stefanie Schmidt, Harriet Sommer, Hans-Iko Huppertz, et al.. Efficacy and safety of pharmacological treatments for Lyme neuroborreliosis in children: a systematic review. BMC Neurology, 2016, 16 (1), pp.189. ⟨10.1186/s12883-016-0708-y⟩. ⟨inserm-02052414⟩
91 View
155 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More